Determination of the Safety of Gadobenate Dimeglumine in Pediatric Subjects Referred for Routine Contrast-Enhanced MR Imaging Procedures

Guenther Schneider¹, Hellmut Schuerholz², Peter Fries², Miles Andrew Kirchin³, Marcus Katoh², Arno Buecker²

A total of 201 pediatric subjects (age range: 0 years 15 years) underwent CE MRI with gadobenate dimeglumine (Gd-BOPTA, MultiHance) as part of clinical routine . Depending on the specific indication patients received a dose of either 0.05 mmol/kg bodyweight (liver, abdominal imaging, musculo-skeletal imaging, brain and other rare indications) or 0.1 mmol/kg bodyweight (cardio-vascular imaging, MR-urography) Gd-BOPTA (MultiHance). Determination of the safety of gadobenate dimeglumine was made by age-group, clinical indication and dose administered. Based on the results of our retrospective analysis, Gd-BOPTA is a save and efficient contrast agent for imaging of pediatric patients. Both in CE-MRA with a dose of 0.1 mmol/kg BW and in abdominal and muscloskeletal imaging at a dose of 0.05 mmol/kg BW no severe adverse events were noted in a total of 201 patients and 316 studies.